GlaxoSmithKline Pakistan Past Earnings Performance
Past criteria checks 1/6
GlaxoSmithKline Pakistan's earnings have been declining at an average annual rate of -8%, while the Pharmaceuticals industry saw earnings growing at 4.1% annually. Revenues have been growing at an average rate of 7.2% per year. GlaxoSmithKline Pakistan's return on equity is 2.5%, and it has net margins of 1.1%.
Key information
-8.0%
Earnings growth rate
-8.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 20.2% |
| Revenue growth rate | 7.2% |
| Return on equity | 2.5% |
| Net Margin | 1.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How GlaxoSmithKline Pakistan makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 49,661 | 534 | 6,528 | 0 |
| 30 Sep 23 | 48,777 | 1,291 | 6,281 | 0 |
| 30 Jun 23 | 46,933 | 1,510 | 6,068 | 0 |
| 31 Mar 23 | 44,615 | 1,968 | 5,557 | 0 |
| 31 Dec 22 | 41,842 | 2,463 | 5,139 | 0 |
| 30 Sep 22 | 40,178 | 3,233 | 4,482 | 0 |
| 30 Jun 22 | 38,078 | 4,280 | 4,014 | 0 |
| 31 Mar 22 | 37,593 | 5,554 | 3,875 | 0 |
| 31 Dec 21 | 36,661 | 5,354 | 3,857 | 0 |
| 30 Sep 21 | 35,082 | 3,907 | 4,063 | 0 |
| 30 Jun 21 | 36,069 | 3,838 | 3,950 | 0 |
| 31 Mar 21 | 34,750 | 3,675 | 3,818 | 0 |
| 31 Dec 20 | 35,090 | 3,375 | 4,064 | 0 |
| 30 Sep 20 | 37,342 | 3,612 | 4,219 | 0 |
| 30 Jun 20 | 34,701 | 3,410 | 4,255 | 0 |
| 31 Mar 20 | 36,248 | 2,934 | 4,192 | 0 |
| 31 Dec 19 | 36,582 | 3,041 | 4,308 | 0 |
| 30 Sep 19 | 34,558 | 3,185 | 4,351 | 0 |
| 30 Jun 19 | 34,436 | 2,802 | 4,452 | 0 |
| 31 Mar 19 | 33,252 | 2,850 | 4,756 | 0 |
| 31 Dec 18 | 34,007 | 3,232 | 4,459 | 0 |
| 30 Sep 18 | 34,165 | 2,621 | 4,538 | 0 |
| 30 Jun 18 | 33,790 | 2,868 | 4,401 | 0 |
| 31 Mar 18 | 33,507 | 3,114 | 4,280 | 0 |
| 31 Dec 17 | 32,774 | 3,027 | 4,130 | 0 |
| 30 Sep 17 | 31,597 | 3,265 | 3,836 | 0 |
| 30 Jun 17 | 30,855 | 3,174 | 3,756 | 0 |
| 31 Mar 17 | 29,840 | 2,900 | 3,721 | 0 |
| 31 Dec 16 | 27,564 | 2,645 | 3,641 | 0 |
| 30 Sep 16 | 26,171 | 2,173 | 3,343 | 0 |
| 30 Jun 16 | 25,062 | 2,716 | 3,349 | 0 |
| 31 Mar 16 | 24,201 | 2,608 | 3,573 | 0 |
| 31 Dec 15 | 23,822 | 2,511 | 3,478 | 0 |
| 30 Sep 15 | 23,322 | 2,421 | 3,708 | 0 |
| 30 Jun 15 | 23,238 | 1,534 | 3,756 | 0 |
| 31 Mar 15 | 22,580 | 1,565 | 3,362 | 0 |
| 31 Dec 14 | 22,843 | 1,535 | 3,458 | 0 |
| 30 Sep 14 | 23,651 | 1,291 | 3,697 | 0 |
| 30 Jun 14 | 23,944 | 1,079 | 3,803 | 0 |
| 31 Mar 14 | 24,875 | 1,103 | 4,301 | 0 |
| 31 Dec 13 | 25,231 | 1,062 | 4,477 | 0 |
| 30 Sep 13 | 24,932 | 1,247 | 4,491 | 0 |
| 30 Jun 13 | 24,058 | 1,338 | 4,292 | 0 |
Quality Earnings: GLAXO has high quality earnings.
Growing Profit Margin: GLAXO's current net profit margins (1.1%) are lower than last year (5.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GLAXO's earnings have declined by 8% per year over the past 5 years.
Accelerating Growth: GLAXO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GLAXO had negative earnings growth (-78.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-3.3%).
Return on Equity
High ROE: GLAXO's Return on Equity (2.5%) is considered low.